{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:40:53Z","timestamp":1789422053433,"version":"build-2803163510"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:italic>Helicobacter pylori (H. pylori)<\/jats:italic>, a globally prevalent pathogen Group I carcinogen, presents a formidable challenge in gastric cancer prevention due to its increasing antimicrobial resistance and strain diversity. This comprehensive review critically analyzes the limitations of conventional antibiotic-based therapies and explores cutting-edge approaches to combat <jats:italic>H. pylori<\/jats:italic> infections and associated gastric carcinogenesis. We emphasize the pressing need for innovative therapeutic strategies, with a particular focus on precision medicine and tailored vaccine development. Despite promising advancements in enhancing host immunity, current <jats:italic>Helicobacter pylori<\/jats:italic> vaccine clinical trials have yet to achieve long-term efficacy or gain approval regulatory approval. We propose a paradigm-shifting approach leveraging artificial intelligence (AI) to design precision-targeted, multiepitope vaccines tailored to multiple <jats:italic>H. pylori<\/jats:italic> subtypes. This AI-driven strategy has the potential to revolutionize antigen selection and optimize vaccine efficacy, addressing the critical need for personalized interventions in <jats:italic>H. pylori<\/jats:italic> eradication efforts. By leveraging AI in vaccine design, we propose a revolutionary approach to precision therapy that could significantly reduce <jats:italic>H. pylori<\/jats:italic> -associated gastric cancer burden.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1500921","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:33:45Z","timestamp":1732775625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Helicobacter pylori-targeted AI-driven vaccines: a paradigm shift in gastric cancer prevention"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhiwei","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junze","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad2545","article-title":"The 5300-year-old Helicobacter pylori genome of the Iceman","volume":"351","author":"Maixner","year":"2016","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2183\/pjab.93.013","article-title":"Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer","volume":"93","author":"Hatakeyama","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110173251603","article-title":"Helicobacter pylori infection and the risk of gastric carcinoma","volume":"325","author":"Parsonnet","year":"1991","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.2.177","article-title":"Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma","volume":"38","author":"Cahill","year":"1996","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13297","article-title":"Mouse models for gastric cancer: Matching models to biological questions","volume":"31","author":"Poh","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa001999","article-title":"Helicobacter pylori infection and the development of gastric cancer","volume":"345","author":"Uemura","year":"2001","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8060173","article-title":"An overview of helicobacter pylori VacA toxin biology","volume":"8","author":"Foegeding","year":"2016","journal-title":"Toxins (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.25.14648","article-title":"cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors","volume":"93","author":"Censini","year":"1996","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901115","article-title":"Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice","volume":"184","author":"Shi","year":"2010","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.3.1263","article-title":"Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation","volume":"97","author":"Stein","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310783","article-title":"Lymphotoxin beta receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner","volume":"66","author":"Mejias-Luque","year":"2017","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1462-5822.2008.01237.x","article-title":"Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation","volume":"11","author":"Tabassam","year":"2009","journal-title":"Cell Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6757","article-title":"CagA promotes proliferation and inhibits apoptosis of GES-1 cells by upregulating TRAF1\/4-1BB","volume":"16","author":"Wang","year":"2017","journal-title":"Mol Med Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218274","article-title":"Exploring the impact of Helicobacter pylori on gut microbiome composition","volume":"14","author":"Dash","year":"2019","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319696","article-title":"Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer","volume":"69","author":"Guo","year":"2020","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.01.017","article-title":"Gastric helicobacter pylori infection affects local and distant microbial populations and host responses","volume":"14","author":"Kienesberger","year":"2016","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001001)89:7<1431::AID-CNCR4>3.0.CO;2-5","article-title":"Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma","volume":"89","author":"Avenaud","year":"2000","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071826","article-title":"Unusual Manifestation of Live Staphylococcus saprophyticus, Corynebacterium urinapleomorphum, and Helicobacter pylori in the Gallbladder with Cholecystitis","volume":"19","author":"Backert","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i19.3038","article-title":"Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients","volume":"12","author":"Nilsson","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq007","article-title":"ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study","volume":"102","author":"Risch","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.08.007","article-title":"Helicobacters and cancer, not only gastric cancer","volume":"86","author":"Varon","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032895","article-title":"Helicobacter pylori and gastric cancer: pathogenetic mechanisms","volume":"24","author":"Salvatori","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.sla.0000149300.28588.23","article-title":"Gastric adenocarcinoma: review and considerations for future directions","volume":"241","author":"Dicken","year":"2005","journal-title":"Ann Surg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.gastro.2015.01.040","article-title":"Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits","volume":"148","author":"Graham","year":"2015","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in helicobacter pylori: A systematic review and meta-analysis in world health organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"B28","article-title":"A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China","volume":"11","author":"Zhong","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2015.05.003","article-title":"How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly","volume":"44","author":"Graham","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"B30","article-title":"Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection","volume":"45","author":"Cheon","year":"2005","journal-title":"Korean J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002629","article-title":"Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial","volume":"136","author":"Suo","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231170052","article-title":"Therapeutic eradication choices in Helicobacter pylori infection in children","volume":"16","author":"Manfredi","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2014.859522","article-title":"Evidence-based recommendations for successful Helicobacter pylori treatment","volume":"8","author":"Wu","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1511427","article-title":"Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies","volume":"16","author":"Graham","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2710.2008.00969.x","article-title":"Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis","volume":"34","author":"Tong","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2008.00593.x","article-title":"Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study","volume":"13","author":"Francavilla","year":"2008","journal-title":"Helicobacter"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-765x.2008.02416.x","article-title":"Isolation of lactobacilli with probiotic properties from the human stomach","volume":"47","author":"Ryan","year":"2008","journal-title":"Lett Appl Microbiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i1.139","article-title":"Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis","volume":"24","author":"Losurdo","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B40","article-title":"Intestinal pathway of internalisation of lactic acid bacteria and gut mucosal immunostimulation","volume":"13","author":"Perdigon","year":"2000","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2108655","article-title":"The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management","volume":"14","author":"Nabavi-Rad","year":"2022","journal-title":"Gut Microbes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13017","article-title":"Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial","volume":"28","author":"Ismail","year":"2023","journal-title":"Helicobacter"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00027-2","article-title":"Multicentre, cross-sectional surveillance of Helicobacter pylori prevalence and antibiotic resistance to clarithromycin and levofloxacin in urban China using the string test coupled with quantitative PCR","volume":"5","author":"Wang","year":"2024","journal-title":"Lancet Microbe"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.477","article-title":"Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori","volume":"40","author":"Versalovic","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1477-1482.2005","article-title":"A Helicobacter pylori TolC efflux pump confers resistance to metronidazole","volume":"49","author":"van Amsterdam","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.05.001","article-title":"Microbiota and gastric cancer","volume":"86","author":"Bessede","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2021.1909459","article-title":"The interplay between Helicobacter pylori and gastrointestinal microbiota","volume":"13","author":"Chen","year":"2021","journal-title":"Gut Microbes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5009\/gnl210593","article-title":"Clinical significance of Epstein-Barr virus and helicobacter pylori infection in gastric carcinoma","volume":"17","author":"Noh","year":"2023","journal-title":"Gut Liver"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/s41467-018-03828-2","article-title":"Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers","volume":"9","author":"Guo","year":"2018","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2983","article-title":"Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer","volume":"46","author":"Wang","year":"2014","journal-title":"Nat Genet"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/ng.982","article-title":"Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer","volume":"43","author":"Wang","year":"2011","journal-title":"Nat Genet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/ijc.24445","article-title":"High-temperature beverages and foods and esophageal cancer risk\u2013a systematic review","volume":"125","author":"Islami","year":"2009","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318247177e","article-title":"Predicting Helicobacter pylori eradication: how to teach an old dog new tricks","volume":"46","author":"Zullo","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i6.1424","article-title":"Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs","volume":"20","author":"Cadamuro","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-9-25","article-title":"pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection","volume":"9","author":"Muller","year":"2011","journal-title":"Cell Commun Signal"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-15138-6_7","article-title":"Role of NOD1 and ALPK1\/TIFA signalling in innate immunity against helicobacter pylori infection","volume":"421","author":"Ying","year":"2019","journal-title":"Curr Top Microbiol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2019_370","article-title":"Immunity and vaccine development against helicobacter pylori","volume":"1149","author":"Walduck","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1342913","article-title":"Strategies of Helicobacter pylori in evading host innate and adaptive immunity: insights and prospects for therapeutic targeting","volume":"14","author":"Fan","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000146","article-title":"Recurrence of Helicobacter pylori infection: incidence and influential factors","volume":"132","author":"Xue","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy075","article-title":"Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination","volume":"217","author":"Machalek","year":"2018","journal-title":"J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12943","article-title":"A comprehensive evaluation of an animal model for Helicobacter pylori-associated stomach cancer: Fact and controversy","volume":"28","author":"Amalia","year":"2023","journal-title":"Helicobacter"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.082","article-title":"Preventive effect of anti-VacA egg yolk immunoglobulin (IgY) on Helicobacter pylori-infected mice","volume":"36","author":"Hong","year":"2018","journal-title":"Vaccine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2007.09.005","article-title":"Helicobacter pylori dampens gut epithelial self-renewal by inhibiting apoptosis, a bacterial strategy to enhance colonization of the stomach","volume":"2","author":"Mimuro","year":"2007","journal-title":"Cell Host Microbe"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1128\/genomeA.00641-15","article-title":"Draft genome sequence of gerbil-adapted carcinogenic helicobacter pylori strain 7.13","volume":"3","author":"Asim","year":"2015","journal-title":"Genome Announc"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.01.009","article-title":"Pattern of transcription factor activation in Helicobacter pylori-infected Mongolian gerbils","volume":"132","author":"Kudo","year":"2007","journal-title":"Gastroenterology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.6.3581-3590.2001","article-title":"Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection","volume":"69","author":"Kotloff","year":"2001","journal-title":"Infect Immun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-015-8666-9","article-title":"Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization","volume":"62","author":"Li","year":"2015","journal-title":"Immunol Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S2468-1253(18)30125-0","article-title":"Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1\/2 study","volume":"3","author":"Malfertheiner","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e2300085","DOI":"10.1002\/adhm.202300085","article-title":"Synthetic Self-Adjuvanted Lipopeptide Vaccines Conferred Protection against Helicobacter pylori Infection","volume":"12","author":"Xue","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1128\/CMR.00006-06","article-title":"Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses","volume":"19","author":"Algood","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101317","article-title":"Immunoglobulin responses at the mucosal interface","volume":"29","author":"Cerutti","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60310-5","article-title":"Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Zeng","year":"2015","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B77","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12934-024-02321-4","article-title":"Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection","volume":"23","author":"Zhang","year":"2024","journal-title":"Microb Cell Fact"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.154","article-title":"Mechanisms of disease: Helicobacter pylori virulence factors","volume":"7","author":"Yamaoka","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2019.104135","article-title":"Genetic diversity and virulence characteristics of Helicobacter pylori isolates in different human ethnic groups","volume":"78","author":"Hanafiah","year":"2020","journal-title":"Infect Genet Evol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.9.2597-2603.1998","article-title":"Expanding allelic diversity of Helicobacter pylori vacA","volume":"36","author":"van Doorn","year":"1998","journal-title":"J Clin Microbiol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70065-x","article-title":"Geographic distribution of vacA allelic types of Helicobacter pylori","volume":"116","author":"Van Doorn","year":"1999","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(97)70223-3","article-title":"Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori","volume":"112","author":"Atherton","year":"1997","journal-title":"Gastroenterology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12951-020-00618-1","article-title":"Effect of the cagW-based gene vaccine on the immunologic properties of BALB\/c mouse: an efficient candidate for Helicobacter pylori DNA vaccine","volume":"18","author":"Chehelgerdi","year":"2020","journal-title":"J Nanobiotechnol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201903847","article-title":"Immunology-guided biomaterial design for mucosal cancer vaccines","volume":"32","author":"Gonzalez","year":"2020","journal-title":"Adv Mater"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq0603","article-title":"Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination","volume":"15","author":"Suberi","year":"2023","journal-title":"Sci Transl Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1438-4221(00)80087-9","article-title":"Genetic variability within Helicobacter pylori","volume":"290","author":"Suerbaum","year":"2000","journal-title":"Int J Med Microbiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1053\/j.gastro.2017.10.014","article-title":"Genome and Methylome Variation in Helicobacter pylori With a cag Pathogenicity Island During Early Stages of Human Infection","volume":"154","author":"Nell","year":"2018","journal-title":"Gastroenterology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70063-6","article-title":"Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults","volume":"116","author":"Michetti","year":"1999","journal-title":"Gastroenterology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.5.634","article-title":"Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers","volume":"51","author":"Banerjee","year":"2002","journal-title":"Gut"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.020","article-title":"Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers","volume":"22","author":"Metzger","year":"2004","journal-title":"Vaccine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.145839","article-title":"Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines","volume":"57","author":"Aebischer","year":"2008","journal-title":"Gut"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-020-00027-9","article-title":"How computational immunology changed the face of COVID-19 vaccine development","author":"Arnold","year":"2020","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1177\/11779322211002168","article-title":"The relevance of bioinformatics applications in the discovery of vaccine candidates and potential drugs for COVID-19 treatment","volume":"15","author":"Chukwudozie","year":"2021","journal-title":"Bioinform Biol Insights"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/s0264-410x(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"B95","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12859-019-2713-9","article-title":"PanRV: Pangenome-reverse vaccinology approach for identifications of potential vaccine candidates in microbial pangenome","volume":"20","author":"Naz","year":"2019","journal-title":"BMC Bioinf"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-8-4","article-title":"VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines","volume":"8","author":"Doytchinova","year":"2007","journal-title":"BMC Bioinf"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/297505","article-title":"Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development","volume":"2010","author":"He","year":"2010","journal-title":"J BioMed Biotechnol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.artmed.2018.12.010","article-title":"Antigenic: An improved prediction model of protective antigens","volume":"94","author":"Rahman","year":"2019","journal-title":"Artif Intell Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-6-35","article-title":"NERVE: new enhanced reverse vaccinology environment","volume":"6","author":"Vivona","year":"2006","journal-title":"BMC Biotechnol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa119","article-title":"Vaxign-ML: supervised machine learning reverse vaccinology model for improved prediction of bacterial protective antigens","volume":"36","author":"Ong","year":"2020","journal-title":"Bioinformatics"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00707-2","article-title":"A guide to antigen processing and presentation","volume":"22","author":"Pishesha","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-015-0873-y","article-title":"Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification","volume":"67","author":"Andreatta","year":"2015","journal-title":"Immunogenetics"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbad011","article-title":"TransMHCII: a novel MHC-II binding prediction model built using a protein language model and an image classifier","volume":"6","author":"Yu","year":"2023","journal-title":"Antib Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab422","article-title":"BERTMHC: improved MHC-peptide class II interaction prediction with transformer and multiple instance learning","volume":"37","author":"Cheng","year":"2021","journal-title":"Bioinformatics"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00442","article-title":"Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools","volume":"11","author":"De Groot","year":"2020","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2020.151949","article-title":"Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus","volume":"225","author":"Ullah","year":"2020","journal-title":"Immunobiology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369890","article-title":"Construction of an aerolysin-based multi-epitope vaccine against Aeromonas hydrophila: an in silico machine learning and artificial intelligence-supported approach","volume":"15","author":"Alawam","year":"2024","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12859-015-0659-0","article-title":"Epitopemap: a web application for integrated whole proteome epitope prediction","volume":"16","author":"Farrell","year":"2015","journal-title":"BMC Bioinf"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-5-17","article-title":"Ab initio modeling of small proteins by iterative TASSER simulations","volume":"5","author":"Wu","year":"2007","journal-title":"BMC Biol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1006","article-title":"The immune epitope database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100700","article-title":"LAFEM: A scoring model to evaluate functional landscape of lysine acetylome","volume":"23","author":"Liang","year":"2024","journal-title":"Mol Cell Proteomics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1500921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:33:50Z","timestamp":1732775630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1500921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":115,"alternative-id":["10.3389\/fimmu.2024.1500921"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1500921","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1500921"}}